Showing 861-870 of 1066 results for "".
- Study Identifies Significant Variations in Pediatric MOGAD Treatmenthttps://practicalneurology.com/news/study-identifies-significant-variations-in-pediatric-mogad-treatment/2473800/The results of a study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 found significant variations in how neurologists treat pediatric individuals with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Res
- Investigational Therapy Significantly Improved Guillain-Barré Syndrome Symptomshttps://practicalneurology.com/news/investigational-therapy-significantly-improved-guillain-barre-syndrome-symptoms/2470935/Treatment with the investigational therapy ANX005 (Annexon, Brisbane, CA) was associated with faster and greater improvements in muscle strength and disability for people with Guillain-Barré syndrome compared with standard therapies such as intravenous immunoglobulin (IVIg) or plasma excha
- Treatment with Ecopipam for Children and Adolescents with Tourette Syndrome Shows No Effect on Psychiatric Comorbiditieshttps://practicalneurology.com/news/treatment-with-ecopipam-for-children-and-adolescents-with-tourette-syndrome-not-linked-to-changes-in-measures-of-adhd-anxiety-ocd-or-depression/2470595/For children and adolescents with Tourette syndrome (TS), treatment with the D1 receptor antagonist ecopipam (Emalex Biosciences, Chicago, IL) was not associated with significant effects on common psychiatric comorbidities in the subgroups of participants with attention deficit disorder (ADHD), a
- Comorbidities Linked with Increased Disease Activity in Individuals with MShttps://practicalneurology.com/news/comorbidities-linked-with-increased-disease-activity-in-individuals-with-ms/2470579/Study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) demonstrated that higher comorbidity burden is associated with increased disease activity in people with multiple sclerosis (MS). This study emphasizes the importance
- Researchers Develop Tool That Reliably Predicts Blood Platelet Hyperreactivity and Risk of Strokehttps://practicalneurology.com/news/researchers-develop-tool-that-reliably-predicts-blood-platelet-hyperreactivity-and-risk-of-stroke/2470566/Results of a study published in Nature Communications reveal the association between platelet hyperreactivity and cardiovascular risk in certain patient populations. In their article, the researchers presented a new tool, the Platelet Reactivity ExpreSsion Score (PRESS), which integrates platelet
- Fecal Microbiota Transplantation Had No Benefit as Parkinson Disease Treatmenthttps://practicalneurology.com/news/fecal-microbiota-transplantation-had-no-benefit-as-parkinson-disease-treatment/2470552/Fecal microbiota transplantation (FMT) was associated with alteration in gut microbiota (GMB) but no clinically meaningful improvements in symptoms vs placebo for people with Parkinson disease (PD), according to results of a clinical trial (NCT04854291) sponsored by the Helsinki University Centra
- New PrecivityAD2 Blood Test as Accurate as CSF Biomarker and Amyloid PET Testinghttps://practicalneurology.com/news/p-tau-blood-tests-potentially-provide-greater-accuracy-and-earlier-diagnosis-for-alzheimer-disease/2470539/Two studies presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) suggest that high-performance blood tests are accurate and effective at assessing f
- Buntanetap Treatment for Parkinson Disease Linked to Improvements in Motor, Non-Motor, and Cognitive Functionshttps://practicalneurology.com/news/buntanetap-treatment-for-parkinson-disease-linked-to-improvements-in-motor-non-motor-and-cognitive-functions/2470527/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with improvements in motor and non-motor activities and cognitive functions in p
- Fintepla Reduced Seizures in Those with Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/fintepla-reduced-seizures-in-those-with-developmental-and-epileptic-encephalopathies/2470519/Results of a meta-analysis published in Epilepsia demonstrated that Fintepla (fenfluramine; UCB, Atlanta, GA) treatment was associated with a reduction in the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in individuals with developmental and epile
- Improvements in Cognition, Alzheimer Disease Biomarkers Linked to Novel Small Molecule Drughttps://practicalneurology.com/news/improvements-in-cognition-alzheimer-disease-biomarkers-linked-to-treatment-with-buntanetap/2470512/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with significant improvements in cognition and biomarker measures in people with